Genes (82)
Species: human : 82 | |
Human | FOXP4 | 116113 | forkhead box P4 | Lastly, FoxP4 matches an uncharacterized human EST that has previously been shown to be down-regulated in larynx carcinoma. | Human | ARL11 | 115761 | ADP-ribosylation factor-like 11 | the G446A in ARLTS1 gene is probably not associated with an increased risk of sporadic breast cancer, prostate cancer, melanoma, thyroid papillary cancer or laryngeal cancer | Human | MYCT1 | 80177 | myc target 1 | AIM: To investigate the expression of c-myc target from laryngeal cancer cells (MTLC) gene in gastric carcinoma (GC) tissues and the effect of MTLC over-expression on gastric carcinoma cell line BGC823. | Human | GGNBP2 | 79893 | gametogenetin binding protein 2 | Previous researches showed LCRG1 might inhibit cell growth, proliferation, colony formation in soft agar, and tumorigenesis of laryngeal carcinoma cell line Hep-2. LCRG1 is a novel gene localized to the tumor suppressor locus D17S800-D17S930 involved in laryngeal carcinoma [Analysis of Differential Proteins in Laryngeal Carcinoma Cell Line Hep-2 with Transfection of LCRG1.] BACKGROUND _amp_ OBJECTIVE: Laryngeal carcinoma-related gene 1 (LCRG1), a novel laryngeal carcinoma-related tumor suppressor gene, was cloned with mRNA differential display method. OBJECTIVES: A novel gene, laryngeal carcinoma-related gene 1 (LCRG1), had the characteristics of tumor-suppressor genes. | Human | GAL3ST2 | 64090 | galactose-3-O-sulfotransferase 2 | In this study, significantly higher expression of Gal3ST-2 (Gal: 3-O-sulfotransferase-2) and 3;-sulfated glycoconjugates were observed in highly metastastic cancer cells and in larynx cancer tissues with lymph node metastasis than those in lowly metastatic cancer cells and larynx cancer tissues without metastasis (P<0.01, n=42). | Human | CAPN10 | 11132 | calpain 10 | These results indicate that some CAPN10 alleles may be exerting a protective effect on laryngeal cancer risk in the Spanish population | Human | BCL10 | 8915 | B-cell CLL/lymphoma 10 | According to the LOH study at intragenic polymorphic sites, deletion of Bcl10 in informative cases was detected in 50% of malignant mesotheliomas, 33% of gastric carcinomas, 23% of breast carcinomas, 20% of hepatocellular carcinomas, 17% of lymphomas, 15% of colorectal carcinomas, 13% of laryngeal carcinomas, and 10% of male germ cell tumors (GCTs). | Human | TP63 | 8626 | tumor protein p63 | METHODS: We studied the expression of dendritic cell (S-100), TIMP-1 and p63 gene on a series of 85 primary laryngeal carcinoma patients who had ever received in our hospital between 1992 and 2000 by the tissuechip technology and SP method. [Expression of S-100 positive dendritic cell, TIMP-1 and p63 and its significance in the primary laryngeal carcinoma] OBJECTIVE: To evaluate the predictive role of S-100 positive dendritic cell, tissue inhibitor of metalloproteinases-1 (TIMP-1) and p63 gene in primary laryngeal carcinoma with epidemiology (smoking and drinking), histological grading, surgical treatment, TNM stage and prognosis by the tissuechip technology. OBJECTIVE: To evaluate the predictive role of S100-positive dendritic cells, tissue inhibitor of metalloproteinase-1 (TIMP1) and p63 gene in laryngeal carcinoma using a tissue chip. MATERIAL AND METHODS: The expression of dendritic cells, TIMP1 and p63 gene in a series of 85 primary laryngeal carcinoma patients who had undergone operations in our hospital between 1992 and 2000 was studied immunohistochemically using the streptavidin-biotin peroxidase-conjugated method. Application of tissue microarray: evaluation of the expression of S-100-positive dendritic cells, tumor suppressor gene p63 and tissue inhibitor of metalloproteinase-1 in laryngeal carcinoma. | Human | LY6D | 8581 | lymphocyte antigen 6 complex, locus D | [Study of cell adhesion in cancer of the larynx] E48 and Ep-CAM are involved in epithelial cell adhesion in healthy and neoplastic tissues. | Human | REEP5 | 7905 | receptor accessory protein 5 | The aim of the present study was to investigate the loss of heterozygosity (LOH), mainly at tumour suppressor loci (using markers D1S2883, D2S123, D3S1611, D5S346, D7S501, D8S254, TP53, NM23), microsatellite instability (BAT25, 26, 40) and <hidden chromosome instability> (bleomycin test) in patients with squamous cell larynx cancer. | Human | ZNF217 | 7764 | zinc finger protein 217 | CCND1 amplifications were associated with the pharyngeal site in primary carcinomas (P < 0.001), whereas amplifications of ZNF217 were less frequent in pharyngeal carcinomas as compared with primary oral and laryngeal carcinomas (P = 0.02). | Human | ZAP70 | 7535 | zeta-chain (TCR) associated protein kinase 70kDa | Both the zeta chain and the Zap 70 expression in circulating T lymphocytes are down-regulated in patients with laryngeal cancer and that these changes do not immediately return to normal after surgery | Human | XRCC3 | 7517 | X-ray repair complementing defective repair in Chinese hamster cells 3 | The distribution of polymorphic variants of XPD, XRCC1 and XRCC3 DNA repair genes in the group of laryngeal cancer subjects (n = 293), subjects with second primary tumours (n = 84) and in the matched controls (n = 322) was estimated by PCR-based genotyping. Five polymorphisms were studied in 3 DNA repair genes. We investigated the effect of XRCC2 Arg(188)His and XRCC3 Thr(241)Met polymorphisms in cancer proneness in 121 oral/pharynx cancer cases, 129 larynx cancer cases and 172 noncancer controls, all Caucasian smokers. | Human | XRCC2 | 7516 | X-ray repair complementing defective repair in Chinese hamster cells 2 | We investigated the effect of XRCC2 Arg(188)His and XRCC3 Thr(241)Met polymorphisms in cancer proneness in 121 oral/pharynx cancer cases, 129 larynx cancer cases and 172 noncancer controls, all Caucasian smokers. | Human | EZR | 7430 | ezrin | And the present study suggests fibronectin and p81 (Ezrin protein) could be the clinical discriminators in laryngeal carcinoma. [Research of fibronectin, p53 and Ezrin protein with occurrence, progress and prognosis in the primary laryngeal carcinoma by the tissuechip technology] OBJECTIVE: To evaluate the predictive role of fibronectin, p81 (Ezrin protein) and p53 gene in primary laryngeal carcinoma, it;s relationship with epidemiology(smoking), histological grading, surgical treatment, TNM stage and prognosis were studied by the tissuechip technology. METHODS: The expression of fibronectin, p53 gene and p81 (Ezrin protein) on a series of 85 primary laryngeal carcinoma patients treated in our hospital between 1992 and 2000 was studied with tissuechip technology. And the present study suggests fibronectin and p81 (Ezrin protein) could be the clinical discriminators in laryngeal carcinoma. | Human | VEGFC | 7424 | vascular endothelial growth factor C | OBJECTIVE: To study the gene expression of Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor C (VEGF-C) in laryngeal carcinoma and their relation with clinic pathologic features. | Human | VEGFA | 7422 | vascular endothelial growth factor A | VEGF, hTERT and Bcl-xl have roles in laryngeal squamous carcinoma | Human | VCAM1 | 7412 | vascular cell adhesion molecule 1 | Correspondingly, VCAM-1 and E-selectin were significantly increased in laryngeal carcinoma, whereas only E-selectin was elevated in oral carcinoma. | Human | TP53 | 7157 | tumor protein p53 | The p53 level was higher than in normal larynxes, whereas laryngeal cancer presented the lowest levels | Human | TOP2A | 7153 | topoisomerase (DNA) II alpha 170kDa | AIM: To determine whether topoisomerase II alpha (topoIIa) expression is an additional prognostic marker for less advanced stage laryngeal cancers first treated without surgery. Expression of topoisomerase II alpha, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation. | Human | TIMP2 | 7077 | TIMP metallopeptidase inhibitor 2 | Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer. MATERIAL/METHODS: The immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 was investigated in 40 laryngeal carcinomas, in order to estimate the prognostic significance of these factors. | Human | TIMP1 | 7076 | TIMP metallopeptidase inhibitor 1 | Expression of MMP-1, TIMP-1, and type I collagen in laryngeal carcinoma. The expression of TIMP-1 was higher in laryngeal cancer than that in pharyngeal cancer, and higher in keratinizing and non-keratinizing SCC than that in basaloid SCC(P<0.05). To our knowledge, however, no previous report examined the histologic localization of matrix metalloproteinase-1 (MMP-1), tissue inhibitor of metalloproteinase-1 (TIMP-1) and Type I collagen in laryngeal carcinoma from the same samples. | Human | TGM3 | 7053 | transglutaminase 3 | [Study on the loss of heterozygosity and expression of transglutaminase 3 gene in laryngeal carcinoma] METHODS: The authors detected the deletion indirectly through loss of heterozygosity (LOH) analysis at DNA level using 4 STR primers within and near TGM3 gene in 72 cases, and detected the differential expression of TGM3 gene in 8 cases of paired normal and cancerous tissue of laryngeal carcinoma by Northern blot. | Human | TFRC | 7037 | transferrin receptor (p90, CD71) | The relationship was studied between the number of transferrin-receptor positive cells and in vitro uptake of 67Ga and 125I-labeled transferrin in human cell lines, including two normal cell lines (WI-38 and foreskin fibroblasts), two transformed cell lines (AV-3 amnionic cells and Chang liver cells), and two neoplastic cell lines (HEp-2, larynx cancer and HeLa, cervical cancer). | Human | TERT | 7015 | telomerase reverse transcriptase | Telomerase activation probably takes place before a cancer phenotype develops and has prognostic significance for survival of patients with laryngeal carcinoma VEGF, hTERT and Bcl-xl have roles in laryngeal squamous carcinoma shRNA directed against hTERT inhibits telomerase activity through suppression of the hTERT expression in laryngeal cancer cells and that RNA interfering technology may be a promising strategy for the treatment of laryngeal cancers |
|